BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 10, 2004
View Archived Issues
Nastech Triples Cash With Public Sale Worth $57.4M
Padding its savings account and then some, Nastech Pharmaceutical Co. Inc. raised about $57.4 million in gross proceeds through a public offering. (BioWorld Today)
Read More
Dynavax's Phase II/III HBV Data Supportive; Phase III Trials Next
Read More
Putting Nobel Prize-Winning Proteasome Research To Use
Read More
With $62M Offering, Array Can Push More Into Clinic
Read More
Other News To Note
Read More